
    
      This is a Phase 1, open-label (all participants and study personnel will know the identity of
      the study treatments) and multicenter (study conducted at multiple sites) study in Japanese
      participants. The study will include a Screening Phase, a Treatment Phase, and a Follow-up
      Phase. The Treatment Phase consists of 2 parts: intense dosing regimen and less intense
      dosing regimen. Follow-up phase will be until 8 weeks after last dose
      administration/death/lost to follow up/consent withdrawal for study participation or study
      end, whichever occurs first. The primary endpoints will be Dose Limiting Toxicity (DLTs) and
      overall Adverse Events (AEs) profiling. Participants' safety will be monitored throughout the
      study.
    
  